);

Innovating healthcare company, Trio Healthcare, sees profits rocket as pioneering products continue to disrupt health-tech market

  • UK based healthcare company has seen its pre-tax profits grow 380% as their innovative healthcare products disrupt health-tech market
  • Trio reports booming profits following win of UK’s most prestigious business accolade – the Queens Award for Enterprise
  • Pioneering company are paving the way for the future of ostomy care following development of silicone gel medical adhesive which is changing the lives of people living with a stoma

A Buckinghamshire based healthcare company dedicated to evolving life enhancing healthcare solutions has announced its pre-tax profits have grown 380% in the last financial year (April 2017-March 2018), an incredible achievement for the UK healthcare sector.

Trio Healthcare, headquartered in Great Missenden, Buckinghamshire have a notable reputation within the sector for developing innovative and advanced medical technologies, such as a silicone gel medical adhesive that prevents abdominal stomas from leaking.

Privately-owned Trio Healthcare also recently won the prestigious Queen’s Award for Enterprise – the UK’s most prestigious business accolade in the Innovation Category for its breakthrough patented silicone technology which is not only improving the lives of ostomates in the UK but in 20 countries around the world too.

The innovative healthcare company and Medilink North of England member is developing market disrupting technology and products in close consultation with patients and clinicians to ensure they are fulfilling gaps and needs of their customers.

Their most recent product to disrupt the market – a unique secure silicone adhesive that can be used around the stoma provides secure but skin-friendly adhesion to the skin. The patented formulation leaves no residue and its hydrophobic nature prevents absorption of any faeces or urine providing a complete barrier, which allows the skin to naturally heal underneath.

The development of the pioneering technology – which is manufactured in house – has enabled Trio to launch a revolutionary range of silicone-based accessory products in an industry dominated by hydrocolloid. These products are viewed as a precursor to the natural next phase of ostomy products coming out of Trio’s pipeline.

Managing Director of Trio Healthcare Lloyd Pearce said: “I’m delighted to see such strong figures for Trio Healthcare. They are a reflection of how hard everyone has been working, researching and developing innovative healthcare. We are a young, dynamic and agile company and these attributes have allowed us to stay ahead of the market and react quickly when conditions change.

“We are an ambitious company and believe we are the company that others look to as setting the standard within this ever-advancing sector. It’s an exciting time for Trio – I look forward to the future where I predict lots more growth and innovation.”

It’s not just the company’s profits that have grown significantly over the last year, Trio Healthcare’s sales growth has increased 62% on the previous year and they are forecasting 55% increase in growth for 2018/19. The company are also investing heavily in research and development, HR and have recently secured a new manufacturing premises in order to develop the next line of Trio Responsive® silicone products.

For more information visit: http://trioostomycare.com/

Comments are closed.